牛牛AI助理已提取核心訊息
On January 17, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, held its 2024 Annual Meeting of Shareholders, where several key proposals were voted upon. The meeting saw the election of Class I and Class II directors, with Brian Szymczak, Bruce Bent, Mark Hilz, and David R. Wells securing their positions. Shareholders approved the full issuance of shares pursuant to an agreement with Lincoln Park Capital Fund, LLC, the 2023 Employee Stock Purchase Plan, and the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2024. Additionally, an amendment to effect a reverse stock split and a change of the corporate name to 'HeartSciences Inc.' were approved. However, the proposal to decrease the number of...Show More
On January 17, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, held its 2024 Annual Meeting of Shareholders, where several key proposals were voted upon. The meeting saw the election of Class I and Class II directors, with Brian Szymczak, Bruce Bent, Mark Hilz, and David R. Wells securing their positions. Shareholders approved the full issuance of shares pursuant to an agreement with Lincoln Park Capital Fund, LLC, the 2023 Employee Stock Purchase Plan, and the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2024. Additionally, an amendment to effect a reverse stock split and a change of the corporate name to 'HeartSciences Inc.' were approved. However, the proposal to decrease the number of shares required for a quorum did not receive sufficient votes, leading to an adjournment to solicit additional votes. The reconvened meeting is scheduled for February 15, 2024, and will be accessible via live webcast. The record date for the Annual Meeting was November 20, 2023, and shareholders who have already voted do not need to recast their votes unless they wish to change their decision on the quorum proposal.
2024年1月17日，心臟測試實驗室有限公司（又名心臟科學）舉行了2024年年度股東大會，會上對幾項關鍵提案進行了表決。會議選舉了一級和二級董事，布萊恩·西姆扎克、布魯斯·本特、馬克·希爾茲和大衛·威爾斯確保了他們的職位。股東批准了根據與林肯公園資本基金有限責任公司達成的協議、2023年員工股票購買計劃以及任命Haskell & White LLP爲截至2024年4月30日的財政年度的獨立註冊會計師事務所的全部股票。此外，一項實施反向股票拆分的修正案以及將公司名稱改爲 “HeartSciences Inc.” 的修正案獲得批准。但是，減少法定人數所需股份數量的提案沒有獲得足夠的選票，因此休會以爭取更多選票。重新召開的會議定於2024年2月15日舉行，將通過網絡直播觀看。年會的創紀錄日期是2023年11月20日，已經投票的股東無需重新投票，除非他們希望更改對法定人數提案的決定。
2024年1月17日，心臟測試實驗室有限公司（又名心臟科學）舉行了2024年年度股東大會，會上對幾項關鍵提案進行了表決。會議選舉了一級和二級董事，布萊恩·西姆扎克、布魯斯·本特、馬克·希爾茲和大衛·威爾斯確保了他們的職位。股東批准了根據與林肯公園資本基金有限責任公司達成的協議、2023年員工股票購買計劃以及任命Haskell & White LLP爲截至2024年4月30日的財政年度的獨立註冊會計師事務所的全部股票。此外，一項實施反向股票拆分的修正案以及將公司名稱改爲 “HeartSciences Inc.” 的修正案獲得批准。但是，減少法定人數所需股份數量的提案沒有獲得足夠的選票，因此休會以爭取更多選票。重新召開的會議定於2024年2月15日舉行，將通過網絡直播觀看。年會的創紀錄日期是2023年11月20日，已經投票的股東無需重新投票，除非他們希望更改對法定人數提案的決定。
有用
沒用